Cargando…
Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease
Autores principales: | Connolly, Caoilfhionn M, Frey, Sarah, Chiang, Teresa Po-Yu, Teles, Mayan, Alejo, Jennifer L, Albayda, Jemima, Shah, Ami A, Werbel, William A, Segev, Dorry L, Christopher-Stine, Lisa, Paik, Julie J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9129174/ https://www.ncbi.nlm.nih.gov/pubmed/35583259 http://dx.doi.org/10.1093/rheumatology/keac298 |
Ejemplares similares
-
Safety and immunogenicity of fifth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series
por: Teles, Mayan S, et al.
Publicado: (2022) -
Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases
por: Connolly, Caoilfhionn M, et al.
Publicado: (2022) -
Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease
por: Frey, Sarah, et al.
Publicado: (2022) -
Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination
por: Frey, Sarah, et al.
Publicado: (2021) -
Durability of Antibody Response Six Months After Two-Dose SARS-CoV-2 mRNA Vaccination in Patients with Cirrhosis
por: Hughes, Robert M., et al.
Publicado: (2023)